News

HinsBet is a new type of prandial insulin, developed using the Company’s proprietary BioChaperone technology, that has been designed to reconcile the performance of insulin analogs with the

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: "We are delighted to expand and deepen our collaboration with Galderma, based on our common ambition to

The terms of the placement are for the purchase of common shares at $1.60 per share and include one warrant per share at an exercise price of $2.24

Actavis’ ANDA product is a generic version of Duchesnay Inc.’s Diclegis, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not

With these latest grants, BrightFocus has now provided more than $8.7 million in research funding in 2014. The research projects funded this year reflect a range of study

The company said that Aptiom is not indicated for use in patients under 18 years of age. The approval is based on three Phase III randomized, double-blind, placebo-controlled,

Beloranib is a potent inhibitor of Methionine aminopeptidase-2 that reduces hunger while stimulating the use of stored fat as an energy source (MetAP2), which is an enzyme that

As part of the deal, the partners will share the costs and risks of discovery and development of new drugs as well as jointly own intellectual property and

The company said that EVZIO is not a substitute for emergency medical care and it is approved by the US Food and Drug Administration (FDA) in April 2014.